Skip to main content

J&J backs out of RSV vaccine race with rivals Pfizer and GSK

J&J lagged behind rival drugmakers Pfizer and GSK, both of which made major strides toward U.S. approval of their RSV vaccines in the last month.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.